Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Expert Opinion on Therapeutic Targets|November 15, 2011
The paradigm of personalized therapy in oncologyGiampietro Gasparini, Raffaele LongoExpert Review of Molecular Diagnostics|July 5, 2008
Anti-VEGF therapy: the search for clinical biomarkersRaffaele Longo, Giampietro GaspariniBiomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 4, 2006
Anti-angiogenic and anti-HER therapyGiampietro Gasparini, Roberta Sarmiento, Raffaele LongoNature Clinical Practice. Oncology|July 3, 2008
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applicationsGiampaolo Tortora, Fortunato Ciardiello, Giampietro GaspariniThe International Journal of Biological Markers|January 3, 2013
Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approachesRoberta Sarmiento, Raffaele Longo, Giampietro GaspariniCurrent Pharmaceutical Design|March 14, 2007
Targeted therapy of breast cancerRaffaele Longo, Francesco Torino, Giampietro GaspariniCritical Reviews in Oncology/Hematology|March 13, 2013
The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancerFrancesco Torino, Roberta Sarmiento, Giampietro GaspariniThe Lancet. Oncology|October 14, 2003
Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?Giampietro Gasparini, Raffaele Longo, Roberta Sarmiento, et al.Nature Clinical Practice. Oncology|November 5, 2005
Angiogenic inhibitors: a new therapeutic strategy in oncologyGiampietro Gasparini, Raffaele Longo, Masakazu Toi, et al.Expert Opinion on Investigational Drugs|April 9, 2010
Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumabRaffaele Longo, Mario D'Andrea, Roberta Sarmiento, et al.Pageof 7